+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae



Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae



Journal of Microbiology, Immunology, and Infection 50(3): 355-361



For extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae infections, carbapenems are recommended as first line therapy, and clinical data on the therapeutic efficacy of fluoroquinolones (FQs) is limited. This study compares the efficacy of FQs and carbapenems for bloodstream infections caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae. Between 2008 and 2010, adults with ESBL-producing E. coli or K. pneumoniae bacteremia at two medical centers were reviewed. Adults receiving definitive FQ or carbapenem therapy were compared in a propensity score-matched analysis, and 30-day mortality was the primary endpoint. A total of 299 patients were eligible. Patients receiving a FQ (n = 24), either ciprofloxacin or levofloxacin, had a lower 30-day mortality rate than those with carbapenem therapy (8.3%, 2/24 vs. 23.3%, 64/275; p = 0.12). Multivariate regression analysis revealed that a critical illness [Pitt bacteremia score ≥ 4 points; odds ratio (OR), 7.09; p < 0.001], rapidly fatal underlying disease (OR, 5.73; p < 0.001), and hospital-associated infection (OR, 2.57; p = 0.01) were independently associated with 30-day mortality. By contrast, FQ definitive therapy was a protective factor compared with carbapenems (OR, 0.18; p = 0.04). There were 72 matched cases with carbapenem therapy in a propensity score-matched analysis, and a difference in the 30-day mortality rate of two groups was noted (8.3% vs. 29.2%; p = 0.05). For ESBL-producing E. coli or K. pneumoniae bacteremia, ciprofloxacin or levofloxacin, if active in vitro, can be considered as a carbapenem-sparing alternative.

(PDF emailed within 0-6 h: $19.90)

Accession: 057888319

Download citation: RISBibTeXText

PMID: 26423244

DOI: 10.1016/j.jmii.2015.08.012


Related references

Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-beta-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli. 2012

Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrobial Agents and ChemoTherapy 56(7): 3936-3942, 2012

Risk factors for bloodstream infections caused by extended-spectrum ?-lactamase-producing Escherichia coli and Klebsiella pneumoniae. The Brazilian Journal of Infectious Diseases 15(4): 370-376, 2011

Risk factors for bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Brazilian Journal of Infectious Diseases 15(4): 370-376, 2012

Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clinical Infectious Diseases 33(8): 1288-1294, 2001

Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrobial Agents and ChemoTherapy 48(12): 4574-4581, 2004

Bloodstream infections due to extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae Risk factors for mortality and clinical outcome, with special emphasis on antimicrobial therapy. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 364, 2003

Risk factors for the emergence of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase -producing Escherichia coli and Klebsiella pneumoniae. Clinical Infectious Diseases 31(1): 212, 2000

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrobial Agents and ChemoTherapy 46(5): 1481-1491, 2002

Risk factors for and mortality of extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections. Revista do Instituto de Medicina Tropical de Sao Paulo 51(4): 211-216, 2009

Risk Factors for Ciprofloxacin Resistance in Bloodstream Infections Due to Extended-Spectrum beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae. Microbial Drug Resistance 10(1): 71-76, 2004

Risk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 365, 2003

Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infection Control and Hospital Epidemiology 29(7): 671-674, 2008

Impact of a clonal outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in the development and evolution of bloodstream infections by K pneumoniae and Escherichia coli an 11 year experience in Oxfordshire, UK. 2011

Bloodstream infections by extended spectrum beta-lactamase -producing Escherichia coli and Klebsiella pneumoniae in children Epidemiologic investigation and clinical outcome. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 420, 2001